EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE


LinkedIn facebook twitter youtube
News archive
Recent news

Myeloma Patients Europe (MPE) is attending the 64th American Society of Hematology (ASH) Annual Meeting, the biggest haematology congress, held from 9 to 13 December in New Orleans (United States). MPE has interviewed haematology experts to summarise the latest updates on myeloma and AL amyloidosis:

 

 

New research presented at the American Society of Hematology meeting focused on Talquetamab in patients with Relapsed/ Refractory myeloma. The study enrolled a total of 288 patients who were unable to tolerate existing therapies or showed disease progression after at least three myeloma therapies. Click here to read more about it.

 

 

 

Lenalidomide maintenance after autologous stem cell transplant (ASCT) is standard of care for myeloma patients. Defining the duration of the treatment is an important question explored in the Myeloma XI clinical trial. Dr Charlotte Pawlyn, Haematology Consultant, Royal Marsden Hospital, London, and member of the Myeloma Patients Europe (MPE) Medical Advisory Committee, explains the latest research presented. Watch the interview here. 

 

COVID-19, and how it affects myeloma and AL amyloidosis patients, was discussed during ASH 2022. Dr Meletios Dimopoulos, Chairman of the Department of Clinical Therapeutics at the National and Kapodistrian University of Athens School of Medicine, Athens, Greece, explains in this video the latest updates on COVID-19 presented. Watch the interview here.

 

 

Dr Meletios Dimopoulos, Chairman of the Department of Clinical Therapeutics at the National and Kapodistrian University of Athens School of Medicine, Athens, Greece, explains in this video the key highlights presented at ASH 2022 and the abstracts he and his team presented at the meeting. You can watch the interview here.

 

 

Dr Charlotte Pawlyn, Haematology Consultant, Royal Marsden Hospital, London, and member of the MPE Medical Advisory Committee, explains the latest CAR-T therapy updates presented at ASH 2022. Watch the interview here.

 

 

 

Watch the interview of Dr Roman Hajek, Head of the Department of Clinical Hematooncology, University Hospital Ostrava, Czech Republic, and member of the MPE Medical Advisory Committee, where he explains the main Minimal Residual Disease (MRD) updates presented at the American Society of Hematology annual meeting 2022. Click here to watch.

 

 

Click here to watch the interview of Dr Roman Hajek, Head of the Department of Clinical Hematooncology, University Hospital Ostrava, Czech Republic, and member of the MPE Medical Advisory Committee, explaining the key highlights presented at the American Society of Hematology annual meeting 2022.

 

 

 

In this video, Dr Charlotte Pawlyn, Haematology Consultant, Royal Marsden Hospital, London, and member of the MPE Medical Advisory Committee, explains the latest bispecific antibodies updates presented at ASH 2022. Click here to watch the interview.

 

 

 

Professor Efstathios Kastritis, Associate Professor at the National and Kapodistrian University of Athens, Athens, Greece, and member of the MPE Medical Advisory Committee, explains the main AL amyloidosis highlights presented at ASH 2022. You can click here to watch the video.

 

 

 

In this video, Professor Efstathios Kastritis, Associate Professor at the National and Kapodistrian University of Athens, Athens, Greece, and member of the MPE Medical Advisory Committee, explains if CAR T-cell therapy is being explored for the treatment of AL amyloidosis. Click here to watch.

 

 

 

 

In this video, Dr Sonja Zweegman, Amsterdam University Medical Centers, Cancer Centers Amsterdam, the Netherlands, and member of the MPE Medical Advisory Committee, explains the myeloma updates and the data she and her team presented at ASH 2022. Click here to watch.

 

 

 

 

Click here to watch the video interview of Dr Sonja Zweegman, Amsterdam University Medical Centers, Cancer Centers Amsterdam, the Netherlands, and member of the Myeloma Patients Europe (MPE) Medical Advisory Committee, explaining the updates for frail and high-risk patients presented at ASH 2022.







Recent news

» Daratumumab approved for first line treatment in Israel

» Join MPE's webinar on doctor and patients’ perspectives on myeloma CAR-T

Leave a Reply

Your email address will not be published. Required fields are marked *

I accept the Privacy Policy